A New Pancreatic Cancer Approval After 30 Years! Optune Pax Receives FDA Approval
In this article
On February 12, 2026, the US Food and Drug Administration (FDA) approved a first-of-its-kind device to treat adults with locally advanced pancreatic cancer. Developed by Novocure, Optune Pax is a portable, noninvasive device that delivers alternating electric fields, known as tumor treating fields (TTFields), to the abdomen. TTFields work by physically disrupting the rapid cell division characteristic of cancer cells while minimizing damage to healthy tissue.
How Does It Work? Invisible Electric Fields
Developed by Novocure, this device does not deliver any medicine into the body. Instead, it targets cancer cells' greatest weakness: rapid division.
A Wearable System
The patient attaches adhesive pads (transducers) to the abdomen. These pads connect to a generator powered by a portable battery.
The TTFields Effect
The device delivers low-intensity alternating electric fields (TTFields) to the abdomen. These electric fields disrupt the internal structure of dividing cancer cells, causing the cells to break apart and die. Healthy cells are less affected because they do not divide or divide slowly.
The PANOVA-3 Study: What Do the Numbers Say?
The FDA approval is based on the study involving 571 patients, PANOVA-3 . Patients using this device alongside standard chemotherapy (gemcitabine + nab-paclitaxel) were compared with patients receiving chemotherapy alone.
- Study Type: Phase 3, randomized, open-label.
- Patient Profile: Patients with inoperable locally advanced pancreatic adenocarcinoma (LAPC).
- Line of Treatment: First-line (patients who had not previously received systemic treatment).
- Arms: Patients were divided into two groups:
Group 1: Standard chemotherapy (gemcitabine + nab-paclitaxel) + Optune Pax (TTFields)
Group 2: Standard chemotherapy alone.
Overall Survival (Median)
Pain-Free Survival (Critically Important)
In pancreatic cancer, pain management is at least as important as survival. The device substantially increased the time spent without pain.
Safety and Cost
The device's most common side effect is skin irritation where the adhesive pads contact the skin (in 75% of patients). The rate of severe (Grade 3) skin reactions is 7.7%.
Cost: It has a high monthly cost of approximately 21000 dollars. This fee includes device rental, pad replacements, and technical support services.
The Turkish Market and the Access Problem: Although the Optune device (a different version) received FDA approval for brain tumors (glioblastoma) in 2015, the manufacturer has not yet introduced it to the Turkish market. The device is not reimbursed by Turkey's Social Security Institution (SGK), and there is currently no distributor network in our country through which it can be obtained privately. Therefore, it may take time for this new FDA approval for pancreatic cancer to translate into an accessible treatment for patients in Turkey.
Technology Is Becoming Integrated into Oncology
The approval of Optune Pax demonstrates that oncology has a place not only for drug molecules but also for biophysical methods. Adapting this technology, previously used for brain tumors (glioblastoma), to a challenging organ such as the pancreas is a major achievement.
In particular, the difference in pain-free survival of 6 months is invaluable for our patients' quality of life. However, the device's high cost and demanding use (continuous carrying and skin care) may create access and adherence challenges. Nevertheless, breaking the 30-year silence is a new ray of hope for pancreatic cancer treatment.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.